CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 60 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00932698
NCT00932698Phase 1Completed
CompareCT.gov

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Millennium Pharmaceuticals, Inc.·interventional·Posted Jul 3, 2009·Updated Aug 7, 2019

In Brief

A Phase 1 clinical trial evaluating Ixazomib for Relapsed and Refractory Multiple Myeloma. Completed, enrolled 60 participants across 5 sites.

Detailed Summary

This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of Ixazomib administered orally in participants with relapsed and/or refractory multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed and Refractory Multiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 3, 2009
Enrollment StartOct 12, 2009
Primary CompletionJun 20, 2013
Study CompletionMay 23, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.0 years ago

Interventions

Ixazomibdrug

Ixazomib capsules